Work

Application of the 2024 McDonald multiple sclerosis criteria in the international Acute Optic Neuritis Network (ACON): a cross-sectional cohort study

Year: 2026
Type: article
Abstract: BACKGROUND: The 2024 McDonald criteria for multiple sclerosis incorporate optic nerve lesions as a fifth topography for dissemination in space, and other additional diagnostic features. We evaluated their performance in patients with acute optic neuritis, a common first manifestation of multiple sclerosis. METHODS: In this cross-sectional cohort analysis from the prospective, multicentre Acute Optic Neuritis Network (ACON) study, we compared the 2024 and 2017 McDonald criteria for multiple sclerosis in patients with a first documented presentation of optic neuritis from 25 centres in 17 countries across six continents. The cohort included patients with idiopathic optic neuritis, clinically isolated syndrome (CIS) according to 2017 McDonald criteria, multiple sclerosis according to 2017 McDonald criteria, aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD), or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). We assessed the sensitivity of the 2017 and 2024 McDonald criteria for diagnosis of multiple sclerosis using data from patients diagnosed, according to the 2017 McDonald criteria, with CIS (defined by presence of MRI lesions in typical locations suggestive of multiple sclerosis or presence of oligoclonal bands) or multiple sclerosis. Specificity was measured with data from the AQP4-IgG-positive NMOSD and MOGAD cohorts. FINDINGS: Between Aug 21, 2020, and Dec 31, 2025, 421 patients were enrolled in ACON. After exclusion of patients with missing information on diagnosis and MRI data, 310 were included in this analysis (59 with idiopathic optic neuritis, 85 with CIS according to 2017 criteria, 85 with multiple sclerosis according to 2017 criteria, 22 with AQP4-IgG-positive NMOSD, and 59 with MOGAD). All patients with multiple sclerosis according to the 2017 McDonald criteria (85 [100%] of 85) fulfilled the 2024 criteria and 27 (32%) of 85 patients with CIS according to the 2017 McDonald criteria were diagnosed as having multiple sclerosis according to the 2024 criteria. Additionally, three (14%) of 22 people with AQP4-IgG-positive NMOSD and six (10%) of 59 people with MOGAD met the 2024 McDonald criteria for multiple sclerosis. The sensitivity of the 2017 criteria was 50% (95% CI 42-58), compared with 66% (95% CI 58-73) for the 2024 criteria, for identification of people with multiple sclerosis among those presenting with a first episode of optic neuritis attributed to multiple sclerosis or CIS according to the 2017 criteria. Specificity of the 2017 criteria was 100% (95% CI 96-100) and that of the 2024 criteria was 89% (95% CI 80-95); diagnostic accuracy of the 2017 criteria was 66% (95% CI 60-72) and that of the 2024 criteria was 73% (95% CI 67-79). INTERPRETATION: In our cohort of patients with a first episode of optic neuritis attributed to multiple sclerosis or CIS according to the 2017 McDonald criteria, the 2024 McDonald criteria enhanced diagnostic sensitivity for multiple sclerosis in people with optic-neuritis-related CIS, potentially enabling earlier diagnosis of multiple sclerosis. However, the criteria reduced specificity in people with optic neuritis related to AQP4-IgG-positive NMOSD and MOGAD, highlighting the need for careful exclusion of alternative diagnoses and further real-world validation. FUNDING: Roche.
Institutions: Max Delbrück Center, Charité – Universitätsmedizin Berlin, Tel Aviv University, Rabin Medical Center, Einstein Center Digital Future, Hospital Ramos Mejía, Koç University, Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi, St. Josef-Hospital, Ruhr University Bochum, Mayo Clinic, Hospital Alemán, Institució Catalana de Recerca i Estudis Avançats, Centre for Biomedical Network Research on Rare Diseases, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, University of Pennsylvania, LMU Klinikum, Institut für Klinische Neuroimmunologie, Ludwig-Maximilians-Universität München, University Medical Center Hamburg-Eppendorf, Institute of Neuroimmunology and Multiple Sclerosis, Hebrew University of Jerusalem, Hadassah Medical Center, University of Verona, University of Botswana, Nitte University, Moorfields Eye Hospital, National Hospital for Neurology and Neurosurgery, University College London, General University Hospital in Prague, University Hospital of Basel, The University of Sydney, Concord Repatriation General Hospital, Tianjin Medical University General Hospital, Siriraj Hospital, Mahidol University, Bumrungrad International Hospital, Vall d'Hebron Hospital Universitari, Centre d'Esclerosi Múltiple de Catalunya, Nanyang Technological University, Duke-NUS Medical School, National Neuroscience Institute, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, University of Colorado Anschutz, University of Colorado Denver, Humboldt-Universität zu Berlin
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $7,280
Funder: Roche
OpenAlex ID: W7236468627
FWCI: 2.563
Cites: 32
Cited by: 1
Related to: 10